These findings clarified that Cav-1 could be considered as a new prognostic biomarker to predict resistance to radiotherapy in NSCLC.85 Recent studies have indicated that paraoxonase 2 (PON2), a lactonase/arylesterase with antioxidant properties, is significantly overexpressed in cancer tissues of NSCLC patients. The gene discussed is CAV1; the disease is non-small cell lung carcinoma.